Geron's (GERN) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Geron (NASDAQ:GERN - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Separately, The Goldman Sachs Group started coverage on shares of Geron in a research report on Thursday, July 10th. They set a "sell" rating and a $1.00 price target for the company. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $3.79.

Geron Price Performance

Shares of NASDAQ GERN opened at $1.38 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 7.87. The company has a 50 day simple moving average of $1.35 and a two-hundred day simple moving average of $1.39. Geron has a fifty-two week low of $1.09 and a fifty-two week high of $4.50. The company has a market capitalization of $880.47 million, a price-to-earnings ratio of -10.62 and a beta of 0.57.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The company had revenue of $49.04 million during the quarter, compared to analyst estimates of $47.30 million. During the same quarter last year, the company earned ($0.10) EPS. The firm's revenue for the quarter was up 5455.6% on a year-over-year basis. Analysts expect that Geron will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Geron

Institutional investors have recently bought and sold shares of the stock. Frisch Financial Group Inc. raised its holdings in Geron by 84.3% in the 1st quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 8,700 shares during the period. StoneCrest Wealth Management Inc. purchased a new position in shares of Geron during the 2nd quarter valued at $35,000. Savant Capital LLC lifted its stake in shares of Geron by 73.8% during the 2nd quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company's stock valued at $37,000 after buying an additional 11,074 shares in the last quarter. Summit Financial Strategies Inc. purchased a new position in shares of Geron during the 2nd quarter valued at $38,000. Finally, Focus Partners Advisor Solutions LLC purchased a new position in shares of Geron during the 1st quarter valued at $39,000. 73.71% of the stock is owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.